INS and Hypoglycemia: The risk of hypoglycemic events with canagliflozin was extremely low in phase III clinical trials, and was most often associated with the use of background insulin or insulin secretagogues (e.g., sulfonylureas) [1]; this low risk of hypoglycemic events is desirable, considering hypoglycemia is associated with higher CV risk [32].